Trial Profile
A retrospective study comparing effectiveness of tyrosine kinase inhibitors afatinib versus erlotinib, gefitinib in patients with advanced-stage lung adenocarcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Erlotinib; Gefitinib
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 13 Apr 2018 New trial record